FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2276403003> ?p ?o ?g. }

• W2276403003 abstract "15003 Background: Recurrent EOC is a common clinical problem and treatment is not curative. We retrospectively analyzed the data on 354 patients with recurrent EOC to determine the impact of various prognostic factors on outcome. Methods: Between August, 1989 and June, 2005, 354 patients (median age 49 years, range, 28 to 80 years) were diagnosed as recurrent EOC. 259 patients received chemotherapy alone, 44 were treated with combination of secondary debulking surgery and chemotherapy or radiotherapy. Remaining 51 (14.4%) patients had no treatment. Main types of salvage chemotherapy included- cisplatin + cyclophosphamide (CP, n = 53), CP + adriamycin (CAP, n = 68), paclitaxel + carboplatin/cisplatin (TP, n = 78). 10 factors were analyzed for survival. Results: 56.5% of patients responded to chemotherapy; complete (CR)-34.2% and partial response (PR) in 22.3% of patients. 124 (35%) patients had no response or progressive disease. 10 (2.8%) died of chemo-toxicity and in remaining 20 status was not known. Median overall survival for patients who received treatment is 19 months vs 3 months for 51 patients who did not receive treatment, p < .001. Predictors of survival were - response to salvage chemotherapy (20 vs 8 months, p < .001), treatment-free interval (>6 months vs ≤ 6 months, 23 vs 9 months p < .001), site of relapse (single vs multiple, 22 vs 16 months, p < .001), Chemotherapy regimen (CP vs CAP vs Paclitaxel + carboplatin) p < .003 on univariate analysis. Age (≤50 years vs >50 years, p = 0.02), initial stage (I vs II vs III vs IV, p = 0.079), histology (serous vs others, p = 0.849), site of relapse (vault vs others, p = 0.156) were not significant predictors. On multivariate logistic regression analysis- response to salvage chemotherapy (HR 0.21, 95% CI 0.15–0.30), treatment-free interval (HR 0.36, 95% CI, 0.20–0.64), and site of relapse (vault vs others, HR 1.22, 95% CI 0.78–1.94) attained significance among 10 factors analyzed. Conclusions: Present study confirms that all patients with recurrent EOC should receive treatment. Response to salvage chemotherapy, a longer treatment-free interval (>6 months) and single site of metastasis are predictors of significantly superior outcome. No significant financial relationships to disclose." @default.
• W2276403003 created "2016-06-24" @default.
• W2276403003 creator A5009728559 @default.
• W2276403003 creator A5021886519 @default.
• W2276403003 creator A5030327070 @default.
• W2276403003 creator A5041331316 @default.
• W2276403003 creator A5048347404 @default.
• W2276403003 creator A5048653843 @default.
• W2276403003 creator A5051317082 @default.
• W2276403003 creator A5059425025 @default.
• W2276403003 date "2006-06-20" @default.
• W2276403003 modified "2023-09-23" @default.
• W2276403003 title "Recurrent epithelial ovarian cancer (EOC): What determines the outcome?" @default.
• W2276403003 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.15003" @default.
• W2276403003 hasPublicationYear "2006" @default.
• W2276403003 type Work @default.
• W2276403003 sameAs 2276403003 @default.
• W2276403003 citedByCount "0" @default.
• W2276403003 crossrefType "journal-article" @default.
• W2276403003 hasAuthorship W2276403003A5009728559 @default.
• W2276403003 hasAuthorship W2276403003A5021886519 @default.
• W2276403003 hasAuthorship W2276403003A5030327070 @default.
• W2276403003 hasAuthorship W2276403003A5041331316 @default.
• W2276403003 hasAuthorship W2276403003A5048347404 @default.
• W2276403003 hasAuthorship W2276403003A5048653843 @default.
• W2276403003 hasAuthorship W2276403003A5051317082 @default.
• W2276403003 hasAuthorship W2276403003A5059425025 @default.
• W2276403003 hasConcept C121608353 @default.
• W2276403003 hasConcept C126322002 @default.
• W2276403003 hasConcept C143998085 @default.
• W2276403003 hasConcept C2780427987 @default.
• W2276403003 hasConcept C29456083 @default.
• W2276403003 hasConcept C2992773878 @default.
• W2276403003 hasConcept C71924100 @default.
• W2276403003 hasConceptScore W2276403003C121608353 @default.
• W2276403003 hasConceptScore W2276403003C126322002 @default.
• W2276403003 hasConceptScore W2276403003C143998085 @default.
• W2276403003 hasConceptScore W2276403003C2780427987 @default.
• W2276403003 hasConceptScore W2276403003C29456083 @default.
• W2276403003 hasConceptScore W2276403003C2992773878 @default.
• W2276403003 hasConceptScore W2276403003C71924100 @default.
• W2276403003 hasLocation W22764030031 @default.
• W2276403003 hasOpenAccess W2276403003 @default.
• W2276403003 hasPrimaryLocation W22764030031 @default.
• W2276403003 hasRelatedWork W151172257 @default.
• W2276403003 hasRelatedWork W1984775533 @default.
• W2276403003 hasRelatedWork W2019696908 @default.
• W2276403003 hasRelatedWork W2062239485 @default.
• W2276403003 hasRelatedWork W2151031435 @default.
• W2276403003 hasRelatedWork W2367907813 @default.
• W2276403003 hasRelatedWork W2403217642 @default.
• W2276403003 hasRelatedWork W2403331838 @default.
• W2276403003 hasRelatedWork W2435413466 @default.
• W2276403003 hasRelatedWork W2468034965 @default.
• W2276403003 isParatext "false" @default.
• W2276403003 isRetracted "false" @default.
• W2276403003 magId "2276403003" @default.
• W2276403003 workType "article" @default.